ArticleGastroenterology research and practice2026
Significance of EGFRvIII Presence in Gastric Adenocarcinoma.
Article in Gastroenterology research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Significance of EGFRvIII Presence in Gastric Adenocarcinoma.Gastroenterology research and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The significance of epidermal growth factor receptor (EGFR) gene variants, particularly the variant known as EGFRvIII, which arises from the deletion of exons 2-8, has been extensively studied in various human carcinomas. In contrast, studies into the role of EGFRvIII in gastric cancer remain limited. The current study aims to evaluate the expression levels of EGFRvIII in patients suffering from gastric adenocarcinoma. Material and methods: In this descriptive cross-sectional study, 21 patients with gastric adenocarcinoma who referred to the university-based referral hospital, Rasoul-Akram, in Tehran, Iran, during 2018-2019, were included. The patients' characteristics including demographic features, medical archives, type and location of tumor mass, and histopathological type were recorded. In order to evaluate the expression of EGFRvIII variant, RT-PCR and sequencing techniques were used. Results: In patients with gastric adenocarcinoma, 14 cases (66.7%) were males and seven cases (33.3%) were females, and the average age of the patients was 66.62 ± 10.79 years, ranging from 45 to 89 years. In terms of the histopathological type, six cases (28.6%) were moderately differentiated (MD), four cases (19.0%) were poorly differentiated (PD), five cases (23.8%) were SIG adenocarcinoma, and six cases (28.6%) were well differentiated (WD). A total of 18 samples (85.7%) were obtained from the biopsy, while three cases (14.3%) were derived from total gastrectomy and necrosis was seen in eight cases (38.1%). Two out of 21 cases (9.5%) were EGFRvIII positive in both RT-PCR and sequencing test. The first case was an 86-year-old woman with a signet-ring cell (SIG) adenocarcinoma tumor subtype with tissue from the antrum and without necrosis. The second case was a 67-year-old man with a tumor subtype of SIG adenocarcinoma with necrotic tissue sample from the gastric cavity. The location of the mutation, two genes on ex1 and ex8, which were connected to each other, was detected in samples of both cases. Conclusion: Our findings showed detection of EGFRvIII in 9.5% of gastric adenocarcinoma cases. Although the sample size presents a limitation, the increase in expression of this variant appears to be independent of the patients' gender and age. Notably, the association of this variant with the signet-ring cell adenocarcinoma subtype is a significant finding that warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.